| | | JVR negative | JVR positive | p value |
| | Number of subjects, n | 36 | 29 | NA | | Age in years, mean (SD) | 52.9 (12.2) | 55.1 (9.3) | 0.422 | | Male gender, n (%) | 27 (75.0) | 24 (82.8) | 0.449 | | History of smoking, n (%) | 14 (38.9) | 13 (44.8) | 0.629 | | History of ICH, n (%) | 0 (0.0) | 4 (13.8) | 0.075 | | History of IS, n (%) | 4 (11.1) | 3 (10.3) | NA | | History of CAD, n (%) | 2 (5.6) | 2 (6.9) | NA | | History of hypertension, n (%) | 29 (80.6) | 26 (89.7) | 0.506 | | Irregular shape of hematoma, n (%) | 5 (13.9) | 9 (36%) | 0.095 | | Admission GCS, median (IQR) | 15 (13–15) | 14 (12–15) | 0.264 | | Admission mRS, median (IQR) | 4 (2–4) | 4 (2–5) | 0.308 | | Admission NIHSS, mean (SD) | 7.8 (5.1) | 8.4 (5.4) | 0.614 | | LDL (mmol/L), mean (SD) | 3.1 (0.9) | 2.8 (0.5) | 0.203 | | GLU (mmol/L), mean (SD) | 5.3 (1.4) | 5.0 (1.3) | 0.509 | | INR, mean (SD) | 1.00 (0.06) | 1.01 (0.04) | 0.214 | | First SBP (mmHg), mean (SD) | 171 (29) | 162 (24) | 0.184 | | First DBP (mmHg), mean (SD) | 99 (16) | 100 (15) | 0.771 | | Baseline hematoma volume (ml), mean (SD) | 19.52 (12.49) | 20.29 (10.85) | 0.794 | | sIVH, n (%) | 6 (16.7) | 5 (17.2) | 1.000 | | Hematoma location in basal ganglia or thalamus, n (%) | 31 (86.1) | 26 (90.0) | 0.958 | | Intraluminal structural abnormality, n (%) | 2 (5.6) | 5 (17.2) | 0.268 | | Malformed valve | 2 (5.6) | 5 (17.2) | — | | Flap | 0 | 0 | | | Web | 0 | 0 | | | Membrane | 0 | 0 | | | Septum | 0 | 0 | | | Extraluminal structural abnormality, n (%) | 0 | 0 | — |
|
|
NA, not applicable; ICH, intracerebral hemorrhage; IS, ischemic stroke; CAD, coronary artery disease; GCS, Glasgow Coma Scale; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; LDL, low density lipoprotein; GLU, blood glucose; INR, international normalized ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; sIVH, secondary intraventricular hemorrhage; IQR, interquartile range; SD, standard deviation; first blood pressure measured after symptom observation.
|
